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background: The use of novel oral anticoagulants (NOACs) such as direct thrombin inhibitors and direct activated Factor X inhibitors in routine 
clinical practice is not well described. We undertook this study to characterize the adoption and patterns of use of NOACs in a sample of outpatient 
cardiology practices.
methods: Using data from July 2009 through June 2012 within the NCDR PINNACLE registry, we examined the rate and type of anticoagulant used 
for patients with non-valvular atrial fibrillation and a CHADS2 score >2. Hierarchical logistic regression analyses then examined temporal trends in 
the use of any anticoagulant and for warfarin and NOACs separately
results: Overall rates of anticoagulation and use of warfarin and NOACs are presented in the table. In the multivariable models, we did not observe 
a significant trend in rates of anticoagulation (p=0.43). However, there was a statistically significant trend in the increasing use of NOACs and 
decreasing use of warfarin (p<0.001). Multivariable models showed that increasing male gender and prior stroke were associated with higher odds 
of receiving NOACs. However, increasing age, higher CHADS2 score and dual antiplatelet therapy were associated with lower likelihood of receiving 
NOACs.
Q3 ’09 Q4 ‘09 Q1 ‘10 Q2 ‘10 Q3 ‘10 Q4 ‘10 Q1 ‘11 Q2 ‘11 Q3 ‘11 Q4 ‘11 Q1 ‘12 Q2 ‘12
Any anti-coagulant 57.3 57.3 57.6 53.9 53.9 52.3 53.7 56.6 55.7 57.0 58.6 57.7
Warfarin 57.3 57.3 57.6 53.9 53.9 51.5 49.1 45.7 46.4 46.3 46.6 44.8
NOACs 0.8 4.6 6.9 9.3 10.7 12.0 12.9
conclusion: Despite increasing adoption of NOACs into clinical practice, the overall rate of anticoagulant treatment in high risk patients with non-
valvular atrial fibrillation has not improved.
